Study ranks S. Dakota third in U.S. for job growth

Study ranks S. Dakota third in U.S. for job growth
South Dakota is among the nation’s top states for job growth, in large part because of its friendly tax base, according to a study from the U.S. Chamber of Commerce. The state has extensive tax and regulatory statutes aimed at lessening the tax burden on doing business, and it invested in infrastructure to promote research and technology development, according to the Enterprising States study …

Read more on The Argus Leader

Modifying Africa: How Biotechnology Can Benefit the Poor and Hungry–A Case Study from Kenya

Product Description
Is the future of Africa full of gloom and doom or is there a glimpse of hope on the horizon? Rather than debate this issue, Dr. Florence Wambugu gives you a hands-on answer in her book Modifying Africa: How Biotechnology Can Benefit the Poor and Hungry; a Case Study From Kenya. She demonstrates how a simple agricultural technology transfer project is helping to break the backbone of poverty and famine.

In Africa, the continent where Dr. Wambugu was born, more than 5,000 people die each day from lack of food. Over 30 million children do not have the required nutrition to live a normal healthy life.

Faced with this grim situation, it is refreshing to see how a simple technology can transform the lives of thousands of poor farmers, who then in turn transform their communities. In Dr. Wambugu’s book Modifying Africa, she writes about real life stories of people who have benefited from planting tissue culture, or clean planting banana seedlings from the lab. If this simple form of technology can change the lives of people, imagine how other sophisticated technologies, such as agribiotech, could possibly transform whole countries? The possibilities are endless.

Modifying Africa is about the nuts and bolts of technology transfer to communities far removed from science and technology. It takes you through a journey that will leave you convinced that through technology, poverty and hunger can be defeated once and for all.

Modifying Africa: How Biotechnology Can Benefit the Poor and Hungry–A Case Study from Kenya

THI at St. Luke’s awarded $1.5M NIH grant for study of stem cells with LVADs for end-stage heart failure

THI at St. Luke’s awarded $1.5M NIH grant for study of stem cells with LVADs for end-stage heart failure
Physician scientists at the Texas Heart Institute at St. Luke’s Episcopal Hospital (THI at St. Luke’s) have been awarded a grant of almost $1.5 million by the National Institutes of Health for research into treatments for patients with end-stage heart failure that would combine heart-assist devices and adult stem-cell treatments.

Read more on News-Medical-Net

Innovation and network structural dynamics: Study of the alliance network of a major sector of the biotechnology industry

Product Description
This digital document is a journal article from Research Policy, published by Elsevier in . The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser.

Description:
We study the large-scale topology and dynamics of maps of alliances in a major segment of the biotechnology industry. The results point to the joint dynamics of network and innovation. The study demonstrates that the network is scale-free. Competition for links translates into a dynamic exponent that seems to follow the fitter-get-richer model of network growth, with preferential attachment to firms holding key technologies. This network also shows a small-world effect. This work highlights the strategic importance of understanding the growth dynamics and structure of collaboration networks for the building of leading positions in industries led by sustained radical change.

Innovation and network structural dynamics: Study of the alliance network of a major sector of the biotechnology industry

Biotech Stocks: Acura tanks; Bayer, Onyx gain on rival’s study

Biotech Stocks: Acura tanks; Bayer, Onyx gain on rival’s study
Acura Pharmaceuticals is the sharpest decliner among the small-cap drug stocks, with shares plunging after an FDA panel votes not to recommend its new painkiller.

Read more on Market Watch

« Previous Page — Next Page »